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Abstract: This article reviews existing clinical practices and sensor research undertaken to monitor
fetal well-being during labour. Current clinical practices that include fetal heart rate monitoring
and fetal scalp blood sampling are shown to be either inadequate or time-consuming. Monitoring
of lactate in blood is identified as a potential alternative for intrapartum fetal monitoring due to its
ability to distinguish between different types of acidosis. A literature review from a medical and
technical perspective is presented to identify the current advancements in the field of lactate sensors
for this application. It is concluded that a less invasive and a more continuous monitoring device is
required to fulfill the clinical needs of intrapartum fetal monitoring. Potential specifications for such
a system are also presented in this paper.
Keywords: lactate; electrochemical sensing; optical sensing; lactate oxidase; lactate hydrogenase;
fetal monitoring; hypoxia; obstetrics; fetal blood sampling
1. Introduction and Clinical Motivation
Fetal monitoring during labor is routinely used in high and middle-income countries to
detect fetuses at risk of hypoxia, acidosis, and associated sequelae including hypoxic-ischemic
encephalopathy, cerebral palsy, and death [1]. Such monitoring involves intermittent or continuous
fetal heart rate monitoring with external ultrasound transducers applied to the maternal abdominal
wall. Continuous cardiotocography (CTG), which was invented in the 1960s [2,3], involves
simultaneous assessment of the fetal heart rate and maternal uterine activity. It is recommended
for intrapartum monitoring in women at high risk of complications [1,4]. While this technique is
non-invasive, it has a low positive and negative predictive value of 30% and 86%, respectively, for the
detection of fetal hypoxia and cerebral palsy [5,6]. This technique, coupled with the high intra-observer
variability in its assessment [7], can lead to unnecessary intervention including a caesarean section [8].
Therefore, CTG is best considered a screening tool for identifying fetuses at risk, which enables
clinicians to further investigate or treat the condition.
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Monitoring of the fetal heart rate through the maternal abdominal wall can sometimes be
difficult. For example, maternal adiposity, the position of the fetus, or twin pregnancy could all
pose complications for monitoring the fetal heart rate. A fetal scalp electrode (FSE) can be applied
directly to the baby’s head to measure heart rate or fetal electrocardiogram (ECG). Although the FSE
usually provides a more stable fetal heart rate signal, there is a higher risk of injury and infection due
to the device needing to puncture the fetal scalp to obtain a signal [9]. The positive predictive value
for detecting fetal hypoxia and cerebral palsy is also no different from that obtained through external
ultrasound transducers.
In an attempt to improve the detection of the fetal compromise, alternative screening methods have
been proposed either as an isolated screening test or in combination with other screening tests such as
CTG. Fetal oxygenation has been measured through a device attached to the clinician’s finger [10,11] or
by directly using a pulse oximetry device embedded into the hook of the FSE [12]. However, although
it is possible to measure fetal oxygenation via the fetal scalp, the addition of fetal pulse oximetry neither
reduces overall caesarean section rates nor improves clinical outcomes [13]. Fetal ECG has also been
developed as a screening method for detecting the intrapartum fetal compromise. Fetal ECG signals
are collected through an FSE with a reference electrode attached to the maternal thigh. Although
initial randomized trials showed that the technology has the potential to reduce unnecessary operative
intervention and neonatal metabolic acidosis [14,15], more recent studies have been equivocal [16,17]
or have not demonstrated benefits [18].
Regardless of what screening test is used, a diagnostic test of fetal well-being is ultimately needed
to inform decision-making. Several methods have been proposed either as an alternative or adjunct to
CTG. Fetal scalp blood sampling (FBS) is the most commonly used since it allows direct measurement of
biochemical parameters of acidosis such as pH, base deficit (BD), and lactate. FBS for pH measurement
was first described by Saling in 1964 [19,20]. The sampling technique, which has changed little since
then, requires cervical dilatation of 3 cm or more for adequate visualization of the fetal scalp using
an amnioscope (a modified speculum), which is inserted vaginally. A small incision is made on the
fetal scalp before collecting 30 to 50 µL of blood into a heparinized capillary tube. The blood is then
analyzed in a blood gas analyzer maintained centrally in the labor ward [21]. This process is invasive,
uncomfortable for women, and time-consuming. It takes between 12 to 25 minutes per sample [22].
Furthermore, it is associated with a failure rate of up to 20% due to technical and operator-related
factors [22,23] such as insufficient sample volume, contamination with air or amniotic fluid [24],
and calibration of the blood gas analyzer at the time of sampling [25]. In the past decade, lactate has
been adopted as an alternative to pH measurand in FBS in Australia and much of Europe since it
appears to be a better predictor of long-term neonatal outcomes. Furthermore, point-of-care meters
have simplified the measurement processes [26,27].
Regardless of the measurand, FBS requires repeated samples to monitor changes in fetal
physiology that can occur rapidly during labor. A continuous, real-time method of assessing the
fetal acid-base status is, therefore, required to enable earlier identification and delivery of the hypoxic
baby before irreversible brain damage occurs. This review explores recent technical advances in the
field of sensors that could help meet the currently unmet clinical need for continuous fetal bio-sensing
during labor.
2. Fetus-Mother Physiology
2.1. Metabolic Pathways During Blood Oxygenation and Deoxygenation
Oxygen (O2) provides the basis for energy production from glucose [28]. The presence or absence
of oxygen leads to different biochemical pathways for energy production, which is shown in Figure 1.
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Figure 1. Aerobic and anaerobic production pathways of ATP. 
In the presence of O2, the human body generates energy in the form of adenosine triphosphate 
(ATP) by producing pyruvate from glucose (glycolysis), its oxidation, and the Krebs cycle. However, 
if the oxygen supply is limited, energy production is less efficient since the pyruvate is broken down 
into lactate nicotinamide adenine dinucleotide (NAD+) by lactate dehydrogenase in the presence of 
the reduced form of nicotinamide adenine dinucleotide (NADH) and hydrogen (H+) ions. NAD+ is 
vital for maintaining limited energy production through glycolysis (red arrow in Figure 1). The 
lactate is itself broken down into lactic acid and H+ ions, which causes the pH value to decrease [29]. 
When oxygen becomes available again, the process is reversed and lactate dehydrogenase converts 
lactate back into pyruvate, which is then used for more efficient energy production in the Krebs cycle 
[29]. There is, therefore, a strong correlation between the presence of oxygen and the production of 
lactate and H+ ions. 
2.2. Physiological Effects of Lack of Oxygenation in the Fetus 
During pregnancy, the provision of gas exchange (O2 and carbon dioxide (CO2)) is carried out in 
utero with the placenta replacing the function of the lungs of the fetus. Deoxygenated blood is 
pumped by the fetal heart through the two umbilical arteries to the placenta while oxygenated blood 
is pumped back into the fetal system through the single umbilical vein. During contractions, the 
perfusion in the placenta can be restricted, which leads to oxygen deficiency [29] and two different 
types of acidosis, which include respiratory and metabolic acidosis. 
• Respiratory acidosis is due to the accumulation of carbon dioxide produced because of normal 
metabolism. Although the concentration of H+ ions increases, respiratory acidosis, in itself, is 
not associated with adverse neurological outcomes because the fetus implements compensatory 
methods [1,30]. 
• Metabolic acidosis occurs when the fetus receives inadequate oxygen to maintain normal 
metabolism, which forces a switch to anaerobic metabolism. This results in the formation of 
lactic acid and, when the buffering capacity of the tissues is exhausted, a decrease in pH. Since a 
lack of oxygen eventually leads to cell death, prolonged exposure to this situation can lead to 
postnatal neurological complications such as short-term hypoxic-ischemic encephalopathy or 
long-term disabilities such as spastic quadriplegia [28]. Profound intrapartum asphyxia can 
result in stillbirth [31] or neonatal death [4,32].  
3. Measurands for the Detection of Fetal Hypoxia  
A range of parameters can be measured in fetal blood sampled during FBS to diagnose fetal 
acidosis and inform clinical management.  
  
Figure 1. Aerobic and anaerobic production pathways of ATP.
In the presence of O2, the human body generates energy in the form of adenosine triphosphate
(ATP) by producing pyruvate from glucose (glycolysis), its oxidation, and the Krebs cycle. However,
if the oxygen supply is limited, energy production is less efficient since the pyruvate is broken down
into lactate nicotinamide adenine dinucleotide (NAD+) by lactate dehydrogenase in the presence of
the reduced form of nicotinamide adenine dinucleotide (NADH) and hydrogen (H+) ions. NAD+ is
vital for maintaining limited energy production through glycolysis (red arrow in Figure 1). The lactate
is itself broken down into lactic acid and H+ ions, which causes the pH value to decrease [29]. When
oxygen becomes available again, the process is reversed and lactate dehydrogenase converts lactate
back into pyruvate, which is then used for more efficient energy production in the Krebs cycle [29].
There is, therefore, a strong correlation between the presence of oxygen and the production of lactate
and H+ ions.
2.2. Physiological Effects of Lack of Oxygenation in the Fetus
During pregnancy, the provision of gas exchange (O2 and carbon dioxide (CO2)) is carried out in
utero with the placenta replacing the function of the lungs of the fetus. Deoxygenated blood is pumped
by the fetal heart through the two umbilical arteries to the placenta while oxygenated blood is pumped
back into the fetal system through the single umbilical vein. During contractions, the perfusion in the
placenta can be restricted, which leads to oxygen deficiency [29] and two different types of acidosis,
which include respiratory and metabolic acidosis.
• Respiratory acidosis is due to the accumulation of carbon dioxide produced because of normal
metabolism. Although the concentration of H+ ions increases, respiratory acidosis, in itself, is not
associated with adverse neurological outcomes because the fetus implements compensatory
methods [1,30].
• Metabolic acidosis occurs when the fetus receives inadequate oxygen to maintain normal
metabolism, which forces a switch to anaerobic metabolism. This results in the formation of
lactic acid and, when the buffering capacity of the tissues is exhausted, a decrease in pH. Since
a lack of oxygen eventually leads to cell death, prolonged exposure to this situation can lead to
postnatal neurological complications such as short-term hypoxic-ischemic encephalopathy or
long-term disabilities such as spastic quadriplegia [28]. Profound intrapartum asphyxia can result
in stillbirth [31] or neonatal death [4,32].
3. Measurands for the Detection of Fetal Hypoxia
A range of parameters can be measured in fetal blood sampled during FBS to diagnose fetal
acidosis and inform clinical management.
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3.1. pH
The normal arterial pH of a healthy fetus is about 7.35 and is regulated primarily by gas exchange
at the placenta. There is a physiological decrease in pH during labor such that the mean umbilical
artery pH at birth is 7.25 [1]. A further decrease in pH may occur as a result of either respiratory or
metabolic acidosis [26,30].
Saling et al. suggested a threshold pH below 7.20 in order to intervene in his original work [33]
and this was supported by later studies, which formed the basis for current international guidelines for
interpreting fetal scalp pH (Table 1). However, large observational studies show that the association
between low pH and neonatal neurological morbidity is weak in babies with an umbilical artery pH
above 7.00 [34,35]. The risk of morbidity only increases significantly when the pH is less than 7.0.
Table 1. Interpretation of fetal scalp blood sampling pH and lactate values.
Measurands Interpretation
pH Lactate
≥7.25 ≤4.1 mmol/L Normal
7.21–7.24 4.2–4.8 mmol/L Borderline
≤7.20 ≥4.9 mmol/L Abnormal
3.2. Base Deficit (BD)
The base deficit (BD) is indicative of the fetal reserves and represents the number of bases that
would neutralize the blood to a pH value ranging between 7.2 and 7.4. The carbonic acid (H2CO3)
−bicarbonate (HCO3−) buffer is represented by Equation (1) [36].
H+ +HCO−3 ↔ H2CO3 ↔ CO2 +H2O (1)
The produced CO2 is eliminated through gas exchange in the placenta [37]. The BD is calculated
from pCO2 and HCO3− by using a derived algorithm (Equation (2)) of the Siggard-Andersen chart [1].
BD = −0.9149·
(
0.12·pCO2·CO2·10pH−6.1 − 24+ 16.21·[pH− 7.4]
)
(2)
The BD helps quantify the metabolic component of an observed change in pH with values above
12.0 mmol/L reflecting severe metabolic acidosis. The pH < 7.00 and BD≥ 12.0 mmol/L are considered
essential criteria for the diagnosis of an acute intrapartum hypoxic event [38] with the BD being used as
an outcome measure examining intrapartum interventions [39–41]. However, the BD is an artificially
calculated parameter and reflects the buffering capacity of the entire body. Different equations are
used to calculate the BD and blood gas analyzers use different algorithms for its determination [36].
It is, therefore, recommended that the BD not be used as a sole parameter for the assessment of
fetal wellbeing.
3.3. Lactate
Lactate, which is the anion that results from the dissociation of lactic acid, is the end product of
anaerobic glucose metabolism. In hypoxic conditions, lactate levels in subcutaneous tissues increase
before pH decreases. Therefore, it appears to be an earlier marker of evolving metabolic acidosis [42].
Fetal scalp lactate during labor and umbilical artery lactate at delivery have been shown to predict
a poor neonatal condition and hypoxic-ischemic encephalopathy better than pH [27]. The introduction
of electrochemical devices, which require only 5 µL of blood and enable the measurement of lactate at
the bedside, also has the potential to reduce the delays and high failure rate associated with FBS for
pH measurement. Several point-of-care sensors have now been validated for intrapartum use with low
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coefficients of variation. However, it is important to note that actual lactate levels and corresponding
thresholds may differ between individual devices. Current devices do not sample continuously [25,26].
Currently recommended clinical thresholds for fetal scalp lactate are outlined in Table 1.
Observational data reported by Kruger et al. suggested that the optimal cut-off value to predict
moderate or severe hypoxic-ischemic encephalopathy was 6.5 mmol/L [27]. Therefore, a lower
threshold for the intervention of 4.8 mmol/L (representing the 75th centile in their high-risk group)
was chosen to prevent rather than predict, adverse outcomes. The corresponding value (25th percentile)
for fetal scalp pH was 7.21 in the same group. Since this closely aligned with the recommended pH
threshold of 7.20, the thresholds above have been widely accepted. There is no difference in neonatal
outcomes or operative interventions seen in randomized trials comparing lactate and pH measurement
in fetal blood sampled when clinically indicated during labor [35]. However, the rate of sampling
and analysis failure appear to be much lower (less than 2%) with point-of-care lactate sensors [43].
For these reasons, lactate is recommended in several national and international guidelines as a more
reliable alternative to fetal scalp pH, but its use has not been universally adopted [4,44]. Of note,
the combined measurement of pH and lactate does not improve the prediction of adverse outcomes
over each method individually [27].
4. Clinical Device Requirements for Ideal Fetal Hypoxia Monitoring Sensor
The device requirements, which are shown in Table 2, need to be fulfilled for a new device to be
used for fetal bio-sensing during labor.
Table 2. Desirable device requirement for detection of fetal hypoxia.
Parameter Functionality
External environment
The device should maintain accuracy and functionality when exposed to
• vaginal secretions, which have a pH of 3.8–4.5
• amniotic fluid, which has a pH of 7–7.5
• a temperature of 35 ◦C to 42 ◦C (maternal environment—external
connections and fetal scalp pH—sampling device)
• movement during contractions and fetus movement down the
birth canal
Biological fluid sampled The device has the potential to sample fetal scalp interstitial fluidand/or fetal blood
Device dimensions and
specifications
The probe should be able to be affixed to the fetal scalp through a cervix,
which is 1 cm or more dilated.
The probe should be no more invasive than an existing FSE.
The probe should be easy to attach and remove from the fetal head
while remaining immobilized against the scalp during contractions or
fetal movements.
The device should be compatible and not interfere with existing external
methods of fetal monitoring (e.g., external CTG).
No separate fetal blood gas/lactate analyzer was required.
The device should be capable of continuous sampling (<5 min intervals)
and measurement of the measurand (s) for a minimum of 12 h.
The material must not degrade during sterilization.
Biocompatibility
The materials used in construction should be biocompatible.
Any chemicals used for sensing must be affixed in a way that ensures
that they do not separate from the sensor surface.
4.1. Accuracy of Measurement
Measurement accuracy and reproducibility is paramount for critical decision-making such as
fetal health. The accuracy of the measurement depends on the sensor and the interaction of the sensor
with the bodily fluid. The measurement of lactate within the fetal blood and the interstitial fluid (ISF),
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which is a solution of sugars, salts, fatty acids, amino acids, and cell waste products that constitute part
of the extracellular fluid. Using a minimally invasive device can affect the accuracy and stability of
the sensors due to biofouling. Biofouling can be caused by factors such as protein adsorption, cellular
adhesion, thrombus formation, and more [45]. The dynamic nature of these effects limits the efficacy
of regular recalibration to ensure accuracy since it cannot be readily determined whether observed
measurement changes are caused by the time-variant properties of these biological films or whether
measurement changes are caused by localized changes due to the presence of metabolically active,
adhered cells, sensor drift, or genuine physiological change. A practical solution is the selection or
modification of materials to prevent these biofouling effects from occurring. Commonly used examples
include the application of a thin film of polyethylene glycol (PEG) to prevent protein adsorption [46,47]
and the utilization of nitric oxide coatings to eliminate thrombus formation [48] as well as limiting the
use of these devices to durations of less than 24 h to minimize these effects.
Another impediment to electrochemical lactate measurement accuracy is the presence of common
electroactive interferents such as acetaminophen, ascorbic acid, and uric acid, which adversely affect
the specificity of in-vivo electrochemical sensors [49,50]. Recent studies have demonstrated that this
interference can be minimized through either the use of compensation electrodes and direct electron
transfer [50] or modification of the electrode material [49,51,52].
4.2. Frequency of Monitoring
A key parameter that must be selected for lactate detection is measurement frequency. Single FBS
samples are both invasive and provide only a single measurement point. More regular measurements
require a sampling location where fluids closely reflect the systemic behavior. For example, less invasive
measurements obtained from the skin must accept that some lag may be present between systemic
lactate levels and those within peripheral blood, interstitial fluid, or sweat. Several studies have
demonstrated a good correlation between venous glucose and ISF glucose in human subjects [53–56].
Some evidence shows that the same is true for lactate [57,58]. For example, in glucose monitoring, there
is a lag of 5 to 6 minutes from intravascular injection to interstitial skin fluid presence [59]. In lactate
(a smaller molecule), low lag times have been observed in mice [60] but, to our knowledge, this work
has not been performed on fetuses. We propose that measuring tissue lactate at 5-minute intervals
would provide sufficient notice of lactate level rises, which act as a practical health monitor.
4.3. Biocompatibility
The challenge of biocompatibility for sensors to be used during pregnancy is twofold since there
is a potential risk to both the mother and the fetus. However, the total duration of sensor use will be
less than ~12 h, which reduces the complications of long-term wound healing responses and occurs
over several days (e.g., macrophage infiltration [61]). The total duration is known to affect other types
of sensors (e.g., continuous glucose monitors [62]).
4.3.1. Risk to the Mother
The risk to the mother can be reduced by using materials and approaches that mirror those used
in current devices used in labor such as the FSE or fetal scalp blood sampling kits. Using an applicator
device such as the ones used in the FSE should also reduce the risk of soft tissue damage to the
mother. Other risks do arise from any potential degradation of the sensor components (e.g., enzyme
and substrate), which results from the amniotic fluid, vaginal secretions, and the temperature of
the environment.
4.3.2. Risk to the Fetus
Sensors that require the skin to be punctured to reach blood or ISF will need to demonstrate that
chemical leaching into the fetus tissue either does not occur or poses no health risk. This is particularly
important when considering how the enzyme is immobilized on the sensor surface. For example,
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devices that make use of Carbon NanoTubes (CNTs) or other materials that risk damaging or irritating
tissues [63] will require strong evidence that they are not released within the fetus tissue. Methods to
improve biocompatibility (and safety) include employing a biocompatible porous polymer layer to
cover the enzyme [64] or locating the enzyme within a hydrogel [65]. Particular attachment chemistries
must also be non-reactive within the skin and not invoke any allergic or irritant response. These will
require substantial safety testing before any use in a fetus.
4.4. Regulatory Device Considerations
There are practical regulatory considerations, which will be affected by device design that must
be taken into account. For example, if the device rests on the baby’s scalp and senses sweat, then
the device will be classed as non-invasive, which leads to a more straightforward path in clinical use.
If a component of the device enters the body and then the risks of infection, tissue reactions, pain and
bleeding become greater, then the sensor is minimally perturbing [62]. In this scenario, the regulatory
pathway will be substantially more arduous with materials, chemicals, and construction being placed
under greater scrutiny. However, this must be balanced against the quality of the signal that can be
achieved from the sensor.
5. Enzyme-Based Lactate Sensors
Enzyme-based lactate sensors can be categorized based on the immobilization method of the
enzymes on the sensor surface and the transduction method used. Immobilization refers to the
attachment of recognition elements such as enzymes either to a substrate or within a support material
to ensure a response to the analyte. The immobilization method chosen can affect the lifetime,
sensitivity, and limit of detection of the sensors [66]. This section describes the various immobilization
methods used in the production of electrochemical and optical lactate sensors shown in Tables 3 and 4.
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Table 3. Summary of various lactate sensors from literature arranged according to the attachment method of the enzyme.
Substrate Enzyme AttachmentMethod Material Transduction Application
Response
Time [s] Sensitivity LoD [pM]
Range of Detection
[pM] Reference
Polymer LOx E (Ent) Carbon paste AM Test solution – – 4.20 × 108 4.20 × 108–8.00 × 108 [49]
Pt LOx C Pt AM Blood andEISF 120 0.2252 µA mM
−1 4.44 × 106 3 to 13 mg dL−1 [58]
NA LOx E (HG) HG P Test solution 912 171.52 µA mM−1 4.44 × 107 – [65]
Pt LDH A CNTs ECL Test solution,sweat – – 8.90 8.90–8.90 ×10
6 [67]
AlGaAs LOx A In-doped ZnO NW AM Test solution 10 – 3.00 3.00–3.00 ×109 [68]
GC LDH A NPs/MWCNT AM Serum – 7.67 µA mM−1 5.00 × 106 5.00 × 107–5.00 × 108 [69]
GC LOx A Carbon ECL Humanserum – – 2.00 × 10
6 2.00 × 106–2.00 × 108 [70]
GC LOx A CNT AM Test solution 2 40.00 µA mM–1 cm–2 4.10 × 106 1.40 × 107–3.25 × 108 [71]
Carbon LOx A Pt-NPs/GCNF-SPCEs AM Foodsamples – 41.30 ± 546 µA mM
−1 cm−2 6.90 × 106 1.00 × 107–3.25 × 108 [72]
Pt LOx A NPs AM Test solution 6 0.0002 µA mM−1 1.00 × 102 5.00 × 108–1.55 × 1010 [73]
OF LDH A – F Test solution,single cell 1 – 2.00 × 10
7 6.00 × 107–1.00 × 109 [74]
Glass LOx E (HG) NA AM Test solution 20 0.0662 µA mM−1 8.00 × 107 8.00 × 107–9.00 × 1010 [75]
Graphene LDH E (SG) Au NPs AM Artificialserum 8 154 µA mM
−1 cm−2 1.30 × 105 1.00 × 107–5.00 × 109 [76]
GC LOx E (SG) Pt NP. MWCNTs AM Whole blood 5 6.36 µA mM−1 3.00 × 108 2.00 × 108–2.00 × 109 [77]
Au LOx E (Ent) Chitosan/CNT AM Test solution 7 19.7 µA mM−1 cm−2 5.00 × 106 – [78]
Graphite LOx E (Ent) Chitosan/CNT AM Test solution,cell culture – 3.417 µA mM
−1 2.26 × 107 3.04 × 107–2.44 × 108 [79]
GC LOx E (SG) Polymer AM – – 1.02 µA mM−1 5.00 × 107 1.00 × 108–9.00 × 109 [80]
Polyimide LOx E (HG) Pt AM – 30 0.005 µA mM−1 mm−2 – – [81]
Plastic LOx E (HG) Glass AM Test solution,dialysate 144 0.00027 µA mM
−1 – 0–1.5 × 1010 [82]
Pt LOx E (SG) SiOx AM Test solution – 180 µA mM−1 cm−2 – 2.00 × 109–8.00 × 109 [83]
Glass LDH E (SG) Si ECL Test solution – – – – [84]
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Table 3. Cont.
Substrate Enzyme AttachmentMethod Material Transduction Application
Response
Time [s] Sensitivity LoD [pM]
Range of Detection
[pM] Reference
Glass
ceramic LOx C Au thin film AM
Test solution,
wine 15 37.1 µA mM
−1 cm−2 5.00 × 106 5×106–1 × 109 [85]
Glass LOx C Al Au OFET Test solution – – 6.60 × 104 0–1 × 1012 [86]
Glass LOx C ZnO NR AM Test solution 10 41.33 ± 1.58 mV/decade 1.00 × 106 1 × 108–1 × 1012 [87]
Pt LOx C HG mucin/albumin AM Blood 90 0.537 µA mM−1 8.00 × 105 2 × 106–1 × 109 [88]
Glass LOx C Carbon film AM
Test
solution/rat
brain
– – 2.30 × 106 5 × 106–5 × 109 [89]
Pt LOx C Monomer AM Foodsamples 60 – 8.00 × 10
6 8 × 106–1 × 109 [90]
PVC LOx C PB nanocubes CV Test solution 5 6.379 µA mM−1 cm−2 1.00 × 107 1 × 107–5 × 108 [91]
Pt LOx C SPEES/PES AM Rats 180 0.001 µA mM−1 – 0–7 × 109 [92]
A = Adsorption, AlGaAs = Aluminium gallium arsenide, AM = Amperometric, C = Cross-linking, CNT = Carbon Nanotube, CV = cyclic voltammetry, E = Encapsulation,
ECL = electrochemiluminescent, Ent = Entrapment, EISF = Extracellular Interstitial Fluid, F = Fluorescence, GC = Glassy carbon, HG = Hydrogel, LDH = Lactate dehydrogenase,
Lox = Lactate oxidase, NP = Nanoparticle, NW = Nanowire, MWCNT = Multiwalled Carbon Nanotube, OF = Optical fibre, OFET = organic field effect transistor, P = Phosphorescence,
PB = Lead, Pt = Platinum, SG = Solgel, Si = Silica, SiOx = Siloxane, SPEES/PES = Sulphonated polyether ether sulphone_polyether sulphone, ZnO = Zinc Oxide.
Table 4. Lactate sensors based on optical detection.
Substrate Enzyme Material Transduction Application Response Time[s] Sensitivity LOD [pM]
Range of Detection
[pM] Reference
None LOx HG Phosphorescent Test solution 912 171.52 µA mM−1 4.44 × 107 – [65]
Pt LDH CNTs ECL Test solution,sweat – – 8.90 8.90–8.90 × 10
6 [67]
GC LOx Carbon ECL Human serum – – 2.00 × 106 2.00 × 106–2.00 × 103 [70]
OF LDH Al coating ECL Test solution,single cell 1 – 2.00 × 10
7 6.00 × 107–1.00 × 109 [74]
Glass LDH Si Fluorescence Test solution – – – – [84]
OF LOx PDMS Colorimetric Test solution 130 – 5.20 × 108 – [93]
Pt = Platinum, GC = glassy carbon, OF = Optical fiber, LDH = Lactate dehydrogenase, Lox = Lactate oxidase, CNTs=Carbon nanotubes, Al = Aluminium, PDMS = Polydimethylsiloxane,
HG = Hydrogel, Si = Silica, ECL = Electrochemiluminescene, CCD = Charged-coupled device, – = Not available.
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5.1. Enzymes
An enzyme is the most commonly used recognition element for lactate detection. Two different
enzymes are used to recognize lactate, which include lactate oxidase (LOx) [65] and lactate dehydrogenase
(LDH) [76]. Enzymatic biosensors have some disadvantages that need to be addressed before wider
clinical translation. Enzyme performance and, therefore, sensor stability is affected by the thermal and the
surrounding chemical environment. Exposure to changes in temperature or pH can affect the performance
and stability of these sensors, which should be taken into account when using these materials [94,95].
One recently used method is through the use of genetically-engineered enzymes even though this may
lead to further regulatory issues [95].
5.1.1. Lactate Oxidase (LOx)
Lactate oxidase (LOx), which is also referred to as lactate mono-oxygenase, promotes the oxidation
of lactate to pyruvate in the presence of oxygen forming hydrogen peroxide (H2O2) [96]. H2O2
is electrochemically active and can be reduced or oxidized to produce an electrical current that is
proportional to the lactate concentration [97]. The reaction does not require a co-factor [85,98]. Compared
to LDH, it requires a lower over-potential, which makes it suitable for electrochemical sensing.
Lactate+O2
LOx→ Pyruvate+H2O2 (3)
H2O2 → O2 + 2H+ + 2e− (4)
The oxidation of H2O2 is preferred as the measurand because the reduction of oxygen is
susceptible to oxygen fluctuations in the sample due to other sources [98] requiring simultaneous
recording of environmental oxygen to ensure accuracy [96]. The dependence of the enzymatic reaction
on oxygen suggests that the effect of oxygen must still be considered when relating the hydrogen
peroxide concentration to the lactate concentration especially for in vivo application. Experiments
carried out in the rat brain suggest that lactate oxidase-based sensors are reliable for in vivo testing and
can tolerate hypoxic conditions. These results suggest that, as long as pO2 is not lower than 10 mmHg,
the sensor reliability is not adversely affected by the surrounding oxygen [99] but may reduce sensor
sensitivity [100].
H2O2 requires a high electrochemical potential to oxidize, which reduces the sensor specificity,
due to increases in interference from other substances in the sample such as ascorbic acid, uric acid,
or acetaminophen [98]. The interference can be eliminated or reduced by covering the sensing surface
with a Nafion® [101] or electro-polymerized thin films [102], which may lead to a decrease in sensitivity.
5.1.2. Lactate Dehydrogenase
LDH is a protein of great importance for the human body. It is released to break down lactate in
damaged tissue or muscles. LDH also promotes the oxidation of lactate to pyruvate. Instead of oxygen,
LDH requires the oxidized form of nicotinamide adenine dinucleotide (NAD+) for the reaction to occur.
NADH, which is the reduced form of NAD+, is the outcome of this reaction (Equations (5) and (6)).
This can then be oxidized [98]. In amperometric sensors, the oxidation current produced by the
oxidation of NADH is directly proportional to the lactate concentration.
Lactate+NAD+ LDH→ Pyruvate+NADH+H+ (5)
NADH→ NAD+ +H+ + 2e− (6)
Unlike LOx, LDH is independent of the presence of oxygen [76,103]. Sensing with LDH does,
however, have a few disadvantages. LDH is an unstable protein and requires a high over-potential of
about 1 V for the oxidation of NADH [104], which can interfere with and reduce the specificity and
stability of the sensor [76,105] due to fouling [105].
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Though the lower over-potential has made lactate oxidase more suitable for the implementation
of electrochemical sensors, the fluorescent properties of the co-factor NADH make it attractive for
the development of optical lactate sensors [67,74,84,106]. Additional reagents such as luminol are
added to achieve more sensitive optical lactate sensors based on LDH [67]. However, luminol is
not biocompatible since it causes skin irritation and has a negative impact on the digestive and the
respiratory system [107]. Such a reagent is, therefore, not suitable for in vivo applications.
5.2. Immobilization Methods
To detect fetal hypoxia, the sensors need to be in direct contact with human tissue.
An immobilization method is, therefore, required, which provides a strong bond between the
enzyme and the electrode surface. It also improves stability and sensor lifetime. For patient safety,
the method should also prevent leaching. There are several methods of attachment including
adsorption, encapsulation, and cross-linking. It is, however, worth noting that current toxicology
and biocompatibility data may indicate risks for some of the nanotechnology approaches (e.g., CNTs or
Nanoparticles) removing the practicality of clinical translation [108].
5.2.1. Adsorption
Physical adsorption is the non-specific physical attachment of enzymes through Van der Waal
forces, hydrogen bonding, or ionic interactions to the sensing surface [109]. This way of immobilization
is simple since neither enzymes nor the support needs to be charged. The support also does not require
much preparation but the lifetime and reproducibility of sensors manufactured with this method are
poor compared to other immobilization methods [66,110]
Ionic adsorption makes use of the electrostatic interaction between ions. The connection between
negatively and positively charged ions is dependent on the surrounding pH, temperature, and ionic
strength and forms the foundation for the ion bonding. Since it is a weak bonding, the enzymes
do not experience much deformation and the immobilization is easily reversed. This reversal can
cause leaching, which makes the sensor less effective and stable [111], and introduces potential
biocompatibility problems.
Covalent adsorption is based on covalent bonding in which two atoms share electrons. While
this immobilization method is a time-consuming process, this attachment method forms a strong
connection between the enzyme and the support material, which makes it more stable and less prone
to leaching. However, this immobilization method can lead to reduced enzyme activity due to enzyme
deformation, limited enzyme movement, and blocking of active sites [112].
5.2.2. Entrapment and Encapsulation
Enzymes can be immobilized by entrapment or encapsulation through the formation of a lattice
or matrix, which enclosed them without forming a connection. Due to the minimal modification
of the enzyme, activity is maintained and the stability of the sensor is increased. Since there is no
connection between the enzyme and the support, the active sites do not get blocked [113] and the
effect of interference from other substances is minimized [98]. However, mass transfer can be impaired
due to the dependency on the porous network surrounding the enzymes. Typical materials used for
entrapment and encapsulation are sol-gel and hydrogel [114]. Sol-gel requires a non-biocompatible
precursor and forms alcohol-causing gel-shrinkage during the manufacturing process [112].
From Table 3, the sensors using sol-gel or hydrogel technology to entrap/encapsulate the lactate
sensing enzymes onto the substrate have the potential to detect lactate concentration as low as
130 nM [76] and 8000 nM [75], respectively. Immobilization through entrapment/encapsulation is
mostly used in combination with amperometric transduction. Although good response times (2–7 s)
have been achieved [77,78,115], such sensors tend to have a slower response time defined in terms of
minutes [65]. This slow response may be due to the diffusion barrier created through the gel around
the enzyme, which is also a protective barrier against the surrounding environment.
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5.2.3. Cross-Linking
Cross-linking uses a two-step process involving the use of reagents to provide sufficient
immobilization. Although this method forms the stable immobilization of the enzyme and does
not require additional support such as gels or membranes, it may cause a conformational change,
which reduces enzyme performance. This method can be improved by using a support material such
as chitosan [112].
Table 3 shows that more than half of the listed sensors utilizing cross-linking offer a sufficient
detection limit needed for fetal monitoring [49,73,80,81,83,85,91,102,116–118]. The response time
ranging from 5 s to 180 s for the electrochemical sensors may not be entirely due to the immobilization
method but could be the result of different protective layers employed, which does not allow for fast
diffusion. However, cross-linking is a common method of immobilizing enzymes. Protocols to achieve
this are readily available [72,88,119–121]. Out of the various methods of immobilization described,
covalent bonding and cross-linking are most likely to provide strong immobilization of the enzyme.
5.2.4. Immobilization for FBS Lactate Sensors
Table 3 classifies lactate sensors by their method of immobilization. More than half of the lactate
sensors surveyed in this literature review are listed as using adsorption to meet the detection limit of
0.001 mM required for FBS [68,69,117,119,122]. Most of those employ amperometry in combination
with LOx [77,119]. The sensors with the lowest detection limit also attach nanoparticles to the sensing
substrate, which acts to increase the specific surface area of the sensor [68,69]. From this table,
an electrochemiluminescence (ECL) sensor also achieved the lowest detection limit [67]. Immobilisation
through adsorption seems to meet the desired specifications as well as through the use of fluorescent
LDH sensors [74].
6. Lactate Sensor Transduction Mechanisms
The main transduction methods used for lactate detection are electrochemical [77,85] and
optical transduction [65,67] even though a microwave-based transduction method was recently
presented [123].
6.1. Optical Sensing
The measurement of lactate concentration by optical means has been around since 1964 [124]
when Broder and Weil measured the blood lactate concentration through the absorption of light. Few
sensors still use absorbance as the method of detecting lactate. Fluorescence and chemiluminescence
are becoming the two most popular methods due to the lower detection limits possible, which is shown
in Table 4. Fluorescence techniques equate the concentration of the analyte with the intensity or lifetime
of the light emitted from the analyte upon excitation by light of a specific wavelength. The Parker
equation, which is shown in Equation (7), can be used to determine the analyte concentration if light
intensity is the measurand where L, IO, φ, ε, C, l, k are the luminescence intensity, excitation source
intensity, luminescence quantum yield, molar absorbance of the analyte at the excitation wavelength,
light path through the analyte solution, and the instrumental constant, respectively [125].
L = 2.31IOϕε[C]lk (7)
Lactate dehydrogenase is the most commonly used enzyme in the production of fluorescent lactate
sensors since its co-enzyme NADH is known to absorb wavelengths between 330 nm to 360 nm and
emit light at wavelengths between 450 nm to 460 nm. The intensity of the light emitted is proportional
to the concentration of NADH and the amount of lactate [96].
Chemiluminescence transducers depend on the emission of light due to a chemical reaction,
which is usually an oxidation reaction caused by oxygen or hydrogen peroxide [112]. Chemiluminescent
lactate sensors are primarily achieved by the reaction between hydrogen peroxide produced by the
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enzymatic reaction and luminol [96]. These sensors are simple to produce and have low detection limits
and a wide dynamic range. However, the underlying chemical reaction to generate light requires the
use of an alkaline medium (pH 8.5–9) to ensure optimal light efficiency, which is undesirable since
enzyme activity requires a pH neutral environment [126]. Various solutions have been proposed for
this conundrum such as photomultiplication tubes [127], two-step enzymatic systems [128], and flow
injection systems [126,129] at the expense of system simplicity. Furthermore, as previously noted,
luminol is not suitable for in vivo applications due to the irritation of the skin and adversely affects the
respiratory and digestive systems [107].
Spectroscopic methods have also been utilized to measure lactate concentrations for in-vivo
biomedical applications [125,130–136]. These are commonly used as a non-invasive method of
measurement for dermatological analysis where a low-power laser beam in the near infrared range
was placed on the skin using an optical fiber or directly scanned over the surface and the resulting
reflected light collected and analyzed for the presence of lactate or other analytes. In-vivo studies
conducted by Pillotto on anesthetized murine models using Raman spectroscopy were able to identify
a change in blood lactate with time, but the limit of detection, sensitivity, and resolution of this method
under these conditions was not reported [131]. The investigation of the molecular composition of the
stratum corneum, which is the outermost layer of the skin, using confocal Raman spectroscopy was
able to detect the presence of lactate but further details were not provided [130]. Other studies using
spectroscopic methods have also reported being able to detect changes in the amount of lactate over
time or in a given area but do not report whether they can measure the actual concentration [134,136].
A recent study was able to produce maps of the concentration per volume of the constituents of the
stratum corneum, such as water, lactate, and lipids. However, no information on the sensor limits
and sensitivity were provided even though the risk of heating of the sample and damage to the skin
was reported due to the lasers required to achieve these maps [135]. All of these studies demonstrate
that the relative concentration of lactate with respect to time or space can be detected. However,
the absolute concentration cannot be detected, which limits the applicability of these methods for
fetal monitoring.
Although optical sensing holds several advantages over electrochemical sensing such as immunity
to electromagnetic interference, electrical isolation from the patient, and ease of miniaturization,
comparatively few researchers have explored optical detection as an alternative method for
determining lactate concentration for in vivo applications. Reasons for this may be due to the fact
that the response of optical sensors can vary from person to person due to skin pigmentation and
epidermal thickness as well as the scattering of light in tissue and the risk of photo-bleaching of the
skin, which have impacted the development of continuous optical glucose monitoring [62].
6.2. Electrochemical Sensing
The majority of the lactate sensors utilize amperometry, which is an electrochemical method for
the analysis of electrochemical cell reactions through the detection of changes in electrical current.
A step in voltage potential, which ranges from −0.2 V to 0.7 V, is applied to a working electrode
with respect to a reference electrode [76,99,115]. Potential electrolysis (reduction or oxidation) takes
place, which is measured as a change in electrical current over time. The electrical current response is
proportional to the concentration of the analyte submitted to the chemical reaction [137]. For planar
electrodes, this response is described by the Cottrell equation shown in Equation (8).
i =
nFAD0.5C
(pit)0.5
(8)
where n is the number of electrons, F is the Faraday constant, A is the electrochemical surface area (cm2),
D is the diffusion coefficient (cm2 s−1), C is the concentration of the electroactive species (mol cm3),
and t is the time in seconds [138]. Amperometric lactate sensors measure the current flow generated
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by electrons, which have been produced either through the breakdown of H2O2 or NADH. These
intermediates originate from LOx and LDH, respectively, which is explained above. The electrical
current measured upon the application of the overpotential is a function of the concentration of the
lactate in the solution.
The amperometric lactate sensors are summarized in Table 4. All sensors listed achieve a detection
limit of 3 pM to 600 nM [68,116]. However, only two of those react within 1 to 6 s [68,73].
The working electrodes have been modified using different materials such as the multi-walled
carbon nanotube (MWCNT) [69,77,139,140], chitosan [141], nanowires [68], and nanoparticles [76,119].
The functionalization before the enzyme immobilization is demonstrated to be one of the more
important fabrication steps of a lactate sensor. The sensors with the quickest reaction time utilizes some
form of nanomaterial since this is thought to generate an increased electrochemical surface area for
attaching the enzyme and for recognizing the lactate. Wei et al. have developed an amperometric lactate
sensor based on a platinum-chitosan electrode functionalized with lactate oxidase, which achieves
a detection limit of 50 nM within 1 s over a period of 24 h [141]. Chitosan is made from the chitin shell
of shrimps and is biocompatible and non-toxic. Windmiller et al. used carbon paste in microneedles
in combination with amperometric transduction [49]. Their research found negligible interference
of other substances. However, their operational stability was only tested for two hours. Ma et al.
developed a lactate sensor using a high electron mobility transistor (HEMT) and zinc oxide (ZnO)
nanowires [68]. In this HEMT based sensor, the drain current represents the lactate concentration in
the sample. Furthermore, the presented sensor does not require a reference electrode, which makes
it possible to minimize the required size of the gate. The gate is fabricated from aluminum gallium
arsenide (AlGaAs), which has high chemical stability and good electron transport properties. However,
toxic effects have been reported for AlGaAs, which makes it unsuitable for medical application with
regard to potential direct contact with the patient [142].
7. Conclusions
Current research studies seem to indicate that electrochemical sensing may be the preferred
modality of lactate sensors whereby either lactate oxidase or lactate dehydrogenase are immobilized
onto the working electrode. Both enzymes have been shown to successfully provide a basis for lactate
sensing. However, a significant proportion of published research focuses on the use of lactate oxidase
as lactate dehydrogenase, which is a less stable protein and requires a larger over-potential.
Covalent bonding and cross-linking have been identified as the most suitable means for
immobilizing the enzymes to the electrode surface. These methods have been found to prevent
leaching of the enzyme, which is important when in contact with human tissue. Encapsulation
requires an additional gel that is not compatible with minimally invasive methods of delivery such
as microneedles.
The study of the available literature has shown that amperometry is the most common
transduction method for lactate sensing. Other means of transduction have been researched but
are not as advanced in their development. The materials used for the working electrode of lactate
sensors include gold, platinum, carbon, and glass, which can be further modified with nanomaterials to
improve sensitivity. Alternative methods of improving sensor performance will need to be investigated.
Since nanomaterials can potentially leach and be toxic, they cannot be utilized for the development of
a fetal sensor.
Finally, the final sensor application must ensure that clinical decisions can be made from the
data obtained from the sensor, which means that minimal lag time and clear data are paramount.
The accuracy and stability of the sensors, which is vital for clinical applications, may be enhanced
through the use of multi-modal sensing including the integration of pH and lactate sensing on the same
platform to compensate for changes in sensor performance due to localized environmental changes.
Achieving this in a small, easy-to-use sensor that can withstand the birthing environment has great
potential to reduce acidosis during birth.
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